Search results
Your search for Haemophilia_A returned no results
Showing 1 to 15 of 27 results for haemophilia
Showing 1 to 15 of 27 results for haemophilia
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1124
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development Reference number: GID-TA10682 Expected publication date: TBC
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Awaiting development Reference number: GID-TA11691 Expected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
In development Reference number: GID-TA11117 Expected publication date: TBC
NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.